Browsing Tag
clinical trials
134 posts
NextCure brings Simcere Zaiming’s SIM0505 to U.S. trials as ADC race accelerates in oncology
Find out how NextCure and Simcere Zaiming are expanding SIM0505’s Phase 1 program into the U.S. and redefining the future of ADC collaboration.
Gyre Therapeutics enrolls 272 patients in late-stage pirfenidone study targeting China’s pneumoconiosis crisis
Gyre Therapeutics completes enrollment of 272 patients in its Phase 3 pirfenidone trial for pneumoconiosis—find out how it could change treatment in China.
Can Protagonist’s icotrokinra become the first oral IL-23 therapy to rival biologics in ulcerative colitis?
Positive Phase 2b data for Protagonist Therapeutics’ oral IL-23R inhibitor icotrokinra show strong efficacy and safety in ulcerative colitis; learn what’s next for Phase 3.
Quoin Pharmaceuticals raises up to $104.5M in private placement to fuel its rare disease pipeline
Find out how Quoin Pharmaceuticals secured up to $104.5 million in a milestone-linked private placement to advance its rare disease therapy QRX003 and strengthen investor confidence.
Cabaletta Bio’s rese-cel CAR-T data at ESGCT 2025 reveal biologic activity without preconditioning in autoimmune disease
Cabaletta Bio’s ESGCT 2025 rese-cel data show early CAR-T activity without chemotherapy preconditioning — see how this could redefine autoimmune therapy.
Enanta Pharmaceuticals to reveal Phase 2b RSV trial results—can zelicapavir change treatment for high-risk adults?
Enanta Pharmaceuticals will present Phase 2b zelicapavir results in RSV high-risk adults. See why this trial matters for investors, patients, and the RSV market.
BeOne Medicines’ sonrotoclax trial hits primary endpoint in mantle cell lymphoma patients
BeOne Medicines’ sonrotoclax met its primary endpoint in mantle cell lymphoma, with positive Phase 1/2 trial results. Find out what this means for patients.
Can Calluna Pharma’s CAL101 finally change the game for idiopathic pulmonary fibrosis patients?
Calluna Pharma begins Phase 2 AURORA trial of CAL101 in idiopathic pulmonary fibrosis, targeting S100A4 for a novel antifibrotic approach.
Coya Therapeutics gets FDA green light for Phase 2 ALS trial with COYA 302
Coya Therapeutics receives FDA clearance to initiate a Phase 2 trial of COYA 302 for ALS. Find out what this means for investors and the ALS drug pipeline.
vTv Therapeutics begins Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes patients
vTv Therapeutics has launched its Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes. Find out what this means for patients and investors today.